Fig. 3. Non-viral, PD1-integrated CAR-T cells potently eliminate tumour cells in patients with r/r B-NHL without serious toxicity.
a, Occurrence of CRS and ICANS after treatment. b, Percentage of CAR+ cells among the peripheral blood T cells of patients on the indicated days before and after infusion. c, CAR copy number in genomic DNA from the peripheral blood of patients on the indicated days before and after infusion. d, Treatment response and duration of response after infusion. PD, progressive disease. e, PET-CT scans of three representative patients before and after treatment. Red arrows indicate tumour lesions.